All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer

被引:162
作者
Coumans, F. A. W. [1 ]
Doggen, C. J. M. [2 ]
Attard, G. [3 ,4 ]
de Bono, J. S. [3 ,4 ]
Terstappen, L. W. M. M. [1 ]
机构
[1] Univ Twente, MIRA Res Inst, Fac Sci & Technol, Dept Med Cell BioPhys, NL-7500 AE Enschede, Netherlands
[2] Univ Twente, Dept Hlth Technol & Serv Res, NL-7500 AE Enschede, Netherlands
[3] Inst Canc Res, Dept Drug Dev Unit, Sutton, Surrey, England
[4] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
关键词
castration-resistant prostate cancer; circulating tumor cell; morphological appearance; tumor microparticle; TUMOR-CELLS; PERIPHERAL-BLOOD; CARCINOMA-CELLS; GENE STATUS; ENUMERATION; EXPRESSION; DISEASE; HER-2; PROGRESSION;
D O I
10.1093/annonc/mdq030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Presence of five or more circulating tumor cells (CTC) in patients with metastatic carcinomas is associated with poor survival. Although many objects positive for epithelial cell adhesion molecules and cytokeratin (EpCAM+CK+) are not counted as CTC, they may be an important predictor for survival. We evaluated the association between these objects and survival in patients with prostate cancer. Patients and methods: Included in this follow-up study were 179 patients with castration-resistant prostate cancer. CellSearch was used to isolate EpCAM+ objects and to stain DNA, cytokeratin and CD45. All EpCAM+CK+ objects were subdivided into seven classes on the basis of predefined morphological appearance in 63 independent samples. Association of each class with survival was studied using Kaplan-Meier and Cox regression analyses. Results: Each EpCAM+CK+CD45- class showed a strong association with overall survival (P < 0.001). This included small tumor microparticles (S-TMP), which did not require a nucleus and thus are unable to metastasize. A higher number of objects in any class was associated with decreased survival. A good prediction model included large tumor cell fragments (L-TCF), age, hemoglobin and lactate dehydrogenase. Models with S-TMP or CTC instead of L-TCF performed similarly. Conclusion: EpCAM+CK+CD45- that do not meet strict definitions for CTC are strong prognostic markers for survival.
引用
收藏
页码:1851 / 1857
页数:7
相关论文
共 31 条
[1]   Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients [J].
Alix-Panabières, C ;
Brouillet, JP ;
Fabbro, M ;
Yssel, H ;
Rousset, T ;
Maudelonde, T ;
Choquet-Kastylevsky, G ;
Vendrell, JP .
JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 299 (1-2) :177-188
[2]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[3]   Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].
Attard, Gerhardt ;
Swermenhuis, Joost F. ;
Olmos, David ;
Reid, Alison H. M. ;
Vickers, Elaine ;
A'Hern, Roger ;
Levink, Rianne ;
Coumans, Frank ;
Moreira, Joana ;
Riisnaes, Ruth ;
Oommen, Nikhil Babu ;
Hawche, George ;
Jameson, Charles ;
Thompson, Emilda ;
Sipkema, Ronald ;
Carden, Craig P. ;
Parker, Christopher ;
Dearnaley, David ;
Kaye, Stan B. ;
Cooper, Colin S. ;
Molina, Arturo ;
Cox, Michael E. ;
Terstappen, Leon W. M. M. ;
de Bono, Johann S. .
CANCER RESEARCH, 2009, 69 (07) :2912-2918
[4]   Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer [J].
Budd, G. Thomas ;
Cristofanilli, Massimo ;
Ellis, Mathew J. ;
Stopeck, Allison ;
Borden, Ernest ;
Miller, M. Craig ;
Matera, Jeri ;
Repollet, Madeline ;
Doyle, Gerald V. ;
Terstappen, Leon W. M. M. ;
Hayes, Daniel F. .
CLINICAL CANCER RESEARCH, 2006, 12 (21) :6403-6409
[5]   Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer [J].
Cohen, S. J. ;
Punt, C. J. A. ;
Iannotti, N. ;
Saidman, B. H. ;
Sabbath, K. D. ;
Gabrail, N. Y. ;
Picus, J. ;
Morse, M. A. ;
Mitchell, E. ;
Miller, M. C. ;
Doyle, G. V. ;
Tissing, H. ;
Terstappen, L. W. M. M. ;
Meropol, N. J. .
ANNALS OF ONCOLOGY, 2009, 20 (07) :1223-1229
[6]   Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer [J].
Cristofanilli, M ;
Hayes, DF ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Reuben, JM ;
Doyle, GV ;
Matera, J ;
Allard, WJ ;
Miller, MC ;
Fritsche, HA ;
Hortobagyi, GN ;
Terstappen, LWMM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1420-1430
[7]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[8]   Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].
de Bono, Johann S. ;
Scher, Howard I. ;
Montgomery, R. Bruce ;
Parker, Christopher ;
Miller, M. Craig ;
Tissing, Henk ;
Doyle, Gerald V. ;
Terstappen, Leon W. W. M. ;
Pienta, Kenneth J. ;
Raghavan, Derek .
CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309
[9]   Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor [J].
de Bono, Johann S. ;
Attard, Gerhardt ;
Adjei, Alex ;
Pollak, Michael N. ;
Fong, Peter C. ;
Haluska, Paul ;
Roberts, Luisa ;
Melvin, Carrie ;
Repollet, Madeline ;
Chianese, David ;
Connely, Mark ;
Terstappen, Leon W. M. M. ;
Gualberto, Antonio .
CLINICAL CANCER RESEARCH, 2007, 13 (12) :3611-3616
[10]  
Harrell FE., 2001, Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis, V608, DOI DOI 10.2147/